148
Participants
Start Date
March 31, 2011
Primary Completion Date
August 31, 2012
Study Completion Date
August 31, 2012
Neupro®
Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
52, Abensberg
53, Alzenau in Unterfranken
18, Beelitz-Heilstätten
42, Bensheim
24, Berlin
27, Berlin
37, Celle
58, Cologne
17, Dillingen
48, Dresden
32, Eisenach
39, Erbach im Odenwald
43, Erfurt
60, Essen
5, Gelnhausen
40, Gelsenkirchen
31, Göttingen
38, Guelders
29, Hagen
57, Halle
6, Halle
28, Hamm
47, Hanover
7, Herborn
55, Hoppegarten
59, Jena
50, Karlstadt am Main
44, Königsbrück
51, Lappersdorf
8, Lohr
4, Marktheidenfeld
45, Merzig
36, Minden
34, Mittweida
35, Mühldorf
25, München
41, München
30, Münster
49, Neuburg am Inn
21, Neumarkt
13, Niederschöna
9, Oschatz
54, Schorndorf
2, Schriesheim
1, Stralsund
12, Stratroda
15, Stuttgard
33, Stuttgart
20, Ulm
14, Unterhaching
22, Weil am Rhein
11, Westerstede
23, Wolfach
56, Wolfratshausen
Lead Sponsor
UCB Pharma
INDUSTRY